Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Forty-one recent cases of invasive zygomycosis from a global clinical registry

Ruping, M. J. G. T., Heinz, W. J., Kindo, A. J., Rickerts, V., Lass-Florl, C., Beisel, C., Herbrecht, R., Roth, Y., Silling, G., Ullmann, A. J., Borchert, K., Egerer, G., Maertens, J., Maschmeyer, G., Simon, A., Wattad, M., Fischer, G., Vehreschild, J. J., Cornely, O. A.·2010·Journal of Antimicrobial Chemotherapy

Abstract

BACKGROUND: Invasive zygomycosis accounts for a significant proportion of all invasive fungal diseases (IFD), but clinical data on the clinical course and treatment response are limited. PATIENTS AND METHODS: Fungiscope-A Global Rare Fungal Infection Registry is an international university-based case registry that collects data of patients with rare IFD, using a web-based electronic case form at www.fungiscope.net. RESULTS: Forty-one patients with invasive zygomycosis from central Europe and Asia were registered. The most common underlying conditions were malignancies (n = 26; 63.4%), diabetes mellitus (n = 7; 17.1%) and solid organ transplantation (n = 4; 9.8%). Diagnosis was made by culture in 28 patients (68.3%) and by histology in 26 patients (63.4%). The main sites of infection were the lungs (n = 24; 58.5%), soft tissues (n = 8; 19.5%), rhino-sinu-orbital region (n = 8; 19.5%) and brain (n = 6; 14.6%). Disseminated infection of more than one non-contiguous site was seen in six patients (14.6%). Mycocladus corymbifer was the most frequently identified species (n = 10, 24.4%). A favourable response was observed in 23 patients (56.1%). Overall survival was 51.2% (n = 21). At diagnosis, four patients (9.8%) were on continuous antifungal prophylaxis with itraconazole (n = 1; 2.4%) or posaconazole (n = 3; 7.3%). Initial targeted treatment with activity against zygomycetes was administered to 34 patients (82.9%). Liposomal amphotericin B was associated with improved response (P = 0.012) and survival rates (P = 0.004). CONCLUSIONS: Pathogen distribution and, consequently, drug susceptibility seem to vary across different geographic regions. Furthermore, protection from invasive zygomycosis for patients on posaconazole prophylaxis is not absolute. Our findings indicate that the use of liposomal amphotericin B as first-line treatment for patients diagnosed with zygomycoses merits further investigation, preferably in the form of a clinical trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkp430

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 201

Metadata

Authors
Ruping, M. J. G. T., Heinz, W. J., Kindo, A. J., Rickerts, V., Lass-Florl, C., Beisel, C., Herbrecht, R., Roth, Y., Silling, G., Ullmann, A. J., Borchert, K., Egerer, G., Maertens, J., Maschmeyer, G., Simon, A., Wattad, M., Fischer, G., Vehreschild, J. J., & Cornely, O. A.
Venue
Journal of Antimicrobial Chemotherapy
Published
2009-12-11
Volume
65
Issue
2
Pages
296-302
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W1985810910
Cited by
201
References
4
FWCI
6.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Forty-one recent cases of invasive zygomycosis from a global clinical registry. https://app.cochat.ai/papers/10.1093/jac/dkp430
The paper
Ruping, M. J. G. T., Heinz, W. J., Kindo, A. J., Rickerts, V., Lass-Florl, C., Beisel, C., Herbrecht, R., Roth, Y., Silling, G., Ullmann, A. J., Borchert, K., Egerer, G., Maertens, J., Maschmeyer, G., Simon, A., Wattad, M., Fischer, G., Vehreschild, J. J., & Cornely, O. A. (2010). Forty-one recent cases of invasive zygomycosis from a global clinical registry. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkp430

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.